Stockscreener 앱 받기
7.54
2.17%
0.16
시장 영업 전:
7.50
-0.04
-0.53%
전일 마감가:
$7.38
열려 있는:
$7.38
하루 거래량:
4.81M
Relative Volume:
1.74
시가총액:
$1.58B
수익:
$331.41M
순이익/손실:
$-226.54M
주가수익비율:
-6.3898
EPS:
-1.18
순현금흐름:
$-97.31M
1주 성능:
-9.27%
1개월 성능:
-16.13%
6개월 성능:
-2.46%
1년 성능:
+41.73%
1일 변동 폭
$7.20
$7.67
1주일 범위
$7.20
$8.355
52주 변동 폭
$4.03
$9.50
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
BCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
7.54 | 1.58B | 331.41M | -226.54M | -97.31M | -1.18 |
|
ZTS
Zoetis Inc
|
164.39 | 73.61B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.90 | 47.03B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.39 | 46.98B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.10 | 18.45B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.24 | 13.95B | 612.78M | -86.37M | -62.91M | -0.87 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-25 | 개시 | Wedbush | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy |
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2020-09-29 | 재개 | JP Morgan | Overweight |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 재개 | Piper Jaffray | Overweight |
| 2018-08-08 | 재개 | JP Morgan | Overweight |
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral |
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 개시 | Barclays | Equal Weight |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | FBR Capital | Outperform |
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition - Investing.com India
BioCryst at Barclays Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada
BioCryst sues to protect ORLADEYO patents By Investing.com - Investing.com Canada
BioCryst Sues Hetero to Block Copies of Drug Worth $386 Million - Bloomberg Law
BioCryst takes legal action to defend rare genetic drug patent; shares fall - TradingView
BioCryst sues to protect ORLADEYO patents - Investing.com India
Biocryst PharmaceuticalsOn March 10, Files Patent Infringement Lawsuit Against Annora And Other Co's - Marketscreener.com
Insider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst Pharmaceuticals Inc (BCRX) - GuruFocus.com
Principal Financial Group Inc. Sells 393,607 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Orladeyo safely prevents swelling attacks in young children with HAE - Angioedema News Today
BioCryst at TD Cowen Conference: Strategic Growth Insights - Investing.com
BioCryst at TD Cowen Conference: Strategic Growth Insights By Investing.com - Investing.com UK
BioCryst Pharmaceuticals Inc (BCRX) Announces Grant of Restricted Stock Units to New Employees - GuruFocus.com
BioCryst reports inducement grants under Nasdaq listing rule - TipRanks
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst's Latest Employee Stock Awards: Key Details on 65,900 RSU Grants - StockTitan
BioCryst CFO resigns, search for successor begins By Investing.com - Investing.com Australia
CFO Anthony Doyle resigns at Biocryst - BioCentury
BioCryst CFO resigns, search for successor begins - Investing.com India
BioCryst CFO Anthony Doyle Resigns Effective April 2025 - TipRanks
Where are the Opportunities in (BCRX) - Stock Traders Daily
Rhumbline Advisers Has $2.33 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
BioCryst stock holds $18 target, JMP bullish on trial results By Investing.com - Investing.com Canada
Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now? - MSN
Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher - MSN
10 Best Small-Cap Stocks to Buy Now - Insider Monkey
BioCryst Pharmaceuticals' (BCRX) "Outperform" Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Wedbush Initiates Coverage on BioCryst Pharmaceuticals (NASDAQ:BCRX) - MarketBeat
HC Wainwright Reiterates Buy Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Earnings Results - MarketBeat
BioCryst stock soars to 52-week high, touches $9.02 - MSN
BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Analysts Set Expectations for BCRX Q1 Earnings - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down Following Weak Earnings - MarketBeat
Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know - MSN
BioCryst: ORLADEYO's Expansion Is Just Getting Started (NASDAQ:BCRX) - Seeking Alpha
BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up (NASDAQ:BCRX) - Seeking Alpha
BioCryst Pharmaceuticals' SWOT analysis: strong orladeyo sales drive stock outlook By Investing.com - Investing.com South Africa
BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical - Seeking Alpha
BioCryst Pharmaceuticals' SWOT analysis: stock outlook amid Orladeyo growth, pipeline shifts - Investing.com Canada
BioCryst Pharmaceuticals’ SWOT analysis: stock outlook amid Orladeyo growth, pipeline shifts - Investing.com India
BioCryst Pharmaceuticals' SWOT analysis: stock outlook amid Orladeyo growth, pipeline shifts By Investing.com - Investing.com South Africa
Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today - MSN
Wedbush bullish on BioCryst, initiates with an Outperform - TipRanks
Earnings call transcript: BioCryst Pharmaceuticals Q4 2024 misses EPS forecast - Investing.com Australia
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2024 Earnings Call Transcript - Insider Monkey
BioCryst Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
BioCryst stock holds Market Outperform amid new targets By Investing.com - Investing.com UK
BioCryst Pharmaceuticals' SWOT analysis: strong orladeyo sales drive stock outlook - Investing.com
BioCryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Highlights: Strong ORLADEYO Revenue ... - Yahoo Finance
BioCryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Highlights: Strong ORLADEYO Revenue ... By GuruFocus - Investing.com Canada
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
7.04%
자본화:
|
볼륨(24시간):